pdufa.bio
CalendarReadoutsDevicesDecisionsApprovals/yrTrial oddsLearnResearchMethodologyCoveragePricing
Home › PDUFA Calendar › RARE

RARE PDUFA Date: UX111

FDA decision (PDUFA) target 2026-09-19 · Ultragenyx Pharmaceutical Inc. · Sanfilippo syndrome type A (MPS IIIA)
More Rare Disease FDA decisions →All September 2026 PDUFA dates →

The story PRIOR CRL

UX111 is under FDA review to treat Sanfilippo syndrome type A (MPS IIIA). Regulatory history: the FDA issued a Complete Response Letter in July 2025 - this PDUFA is the resubmission. Balance sheet: about 10 months of cash, runway ~10 mo (estimated). ELEVATED — under 12 months
Full PDUFA calendar ->Every upcoming FDA decision date, by monthNVO-sogroya . 2026-06-30Same area: Rare / Genetic . Sogroya (somapacitan)REGN-otoferlin-gene-therapy . 2026-06-30Same area: Rare / Genetic . Otoferlin gene therapy (DB-OTO)TLX . 2026-09-11Same month decision . TLX101-Px
Plain-English summary compiled by pdufa.bio from public FDA, SEC and company sources. Informational only - not investment advice.

RARE run-up into the PDUFA (last ~120 days)

$26.91$18.5
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-09-19
Drug / candidateUX111
IndicationSanfilippo syndrome type A (MPS IIIA)
CompanyUltragenyx Pharmaceutical Inc.
Market-cap tierMid
Cohort decision-day move (history)±2% median
ClinicalTrials.govNCT02716246

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the RARE PDUFA date?
The FDA PDUFA target date for RARE (Ultragenyx Pharmaceutical Inc.) is 2026-09-19 for UX111. Dates are company/FDA-sourced and can slip — verify against primary filings.
What is RARE's drug UX111?
UX111 is Ultragenyx Pharmaceutical Inc.'s candidate under FDA review for Sanfilippo syndrome type A (MPS IIIA).
What typically happens to a mid-cap stock into a PDUFA date?
Historically, mid-cap names had a median decision-day move around ±2% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.